Journal articleChest · February 2026
BACKGROUND: Severe asthma affects 5% to 10% of patients with asthma but constitutes close to one-half of the medical costs related to asthma due to higher morbidity and health care utilization. Biologic agents have become a standard of care in those unresp ...
Full textLink to itemCite
Journal articleJ Allergy Clin Immunol Pract · September 2022
BACKGROUND: Adherence barriers to asthma biologics may not be uniform across administration settings for patients with moderate-to-severe asthma. OBJECTIVE: To examine differences in asthma biologic adherence and associated factors, as well as association ...
Full textOpen AccessLink to itemCite
Journal articleFront Physiol · 2022
Excessive decrease in the flow of the late expiratory portion of a flow volume loop (FVL) or "flattening", reflects small airway dysfunction. The assessment of the flattening is currently determined by visual inspection by the pulmonary function test (PFT) ...
Full textOpen AccessLink to itemCite
Journal articlePatient Prefer Adherence · 2021
Moderate-to-severe asthma represents about a quarter of the nearly 10% of Americans diagnosed with asthma. Many patients with moderate-to-severe asthma have uncontrolled symptoms that lead to exacerbations requiring oral corticosteroids. There are many fac ...
Full textOpen AccessLink to itemCite